louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05204316: NLP Headache Speech (NLPH-SPEECH): a Cross-sectional Study on Natural Language Processing Analysing Spoken Monologues by Headache Patients
Official title: NLP Headache Speech (NLPH-SPEECH): a Cross-sectional Study on Natural Language Processing Analysing Spoken Monologues by Headache Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Headache Disorders
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2022-01-24
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The research collects spoken descriptions of headache disorders by participants with headache disorders. The speech recordings are analyzed by natural language processing (NLP) tools to analyse linguistic properties of the texts and to obtain insight into the potential of NLP machine learning models for the recognition of headache syndromes of the participants.


Eligibility criteria: Inclusion Criteria:

* is a patient of the tertiary headache clinic at Ghent University Hospital
* is 18 years or older
* has Dutch as native speaking language

Exclusion Criteria:

* has difficulties in producing spoken language
* has limited or no knowledge of Dutch

Primary outcomes:
measure: Linguistic analysis of texts
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: Machine learning modelling for classification of headache disorders
timeFrame: through study completion, an average of 1 year
measure: Machine learning modelling for estimation of headache impact scores
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Gent
country: Belgium
facility: UZ Gent - Dienst Neurologie
Study officials:
References:
Clinical trial NCT02144116: Dance-movement Therapy Programme in Fibromyalgia.
Official title: Effects of a Dance-movement Therapy Programme in Patients With Fibromyalgia.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Fibromyalgia
Keywords: dance-movement therapy
balance
Fibromyalgia
Lead sponsor: Universidad de Granada
Sponsor class: OTHER
First posted: 2014-05-21
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Fibromyalgia is a chronic illness characterized by persistent widespread muscle pain with generalized hyperalgesia and allodynia. It can be accompanied by other concomitant symptoms like fatigue, sleep disturbances, musculoskeletal disorders, distress and psychological disorders. This condition is very prevalent. It has been reported to be about 2-5% of the general global population. Fibromyalgia is associated with balance problems and increased fall frequency. The objective of this study was to examine the effects of an 8 weeks dance-movement therapy programme on balance, strength, flexibility and quality of life in patients with fibromyalgia.

Detailed description: Fibromyalgia is a chronic condition associated with balance problems and pain. It has been previously described that fibromyalgia may affect peripheral and/or central mechanisms of postural control. Balance or postural stability is a very complex task that involves the integration of multiple sensory inputs to execute appropriate neuromuscular activity needed to maintain balance.

Patients with fibromyalgia have also muscle weakness. Muscle strength depends on both the cross-sectional area of the muscle and the neural activity. Range of movement and quality of life have also been reported to be affected.

Eligibility criteria: Inclusion Criteria:

* Women diagnosed of Fibromyalgia attending to the Fibromyalgia Association of Granada.
* Women who can complete the assessment battery of tests at the beginning and at the end of the study

Exclusion Criteria:

* Auditive and visual disturbances.
* Cognitive problems.
* Psychiatric pathology.
* Traumatic pathology of lower limbs.

Primary outcomes:
measure: Changes in balance
timeFrame: Baseline, 8 weeks
Secondary outcomes:
measure: Changes in quadriceps strength
timeFrame: Baseline, 8 weeks
measure: Changes in quality of life
timeFrame: Baseline, 8 weeks
measure: Changes in flexibility of lower limbs
timeFrame: Baseline, 8 weeks
Other outcomes:
Locations:
city: Granada
country: Spain
facility: University of Granada
Study officials:
affiliation: Universidad de Granada
name: Marie Carmen Valenza, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04420416: Mental Health and Academic Performance in COVID-19
Official title: dePression, Anxiety, aNd acaDemic pErforMance In Covid-19: PANDEMIC Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Depression, Anxiety
Keywords: COVID-19
Depression
Anxiety
Public health
Academic performance
Lead sponsor: Instituto Mexicano del Seguro Social
Sponsor class: OTHER_GOV
First posted: 2020-06-09
Enrollment: 720
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Undergraduate and graduate students who attend an online university course.

Brief summary: This study aims to identify the preference of the class modalities (classroom or online) in undergraduate and graduate students. Additionally, to explore if the presence of any mental state alterations such as depression or anxiety due to the COVID-19 pandemic can alter their perception of academic performance.


Eligibility criteria: Inclusion Criteria:

* \> 18 years
* Students of any undergraduate or graduate course who are attending their semester online

Exclusion Criteria:

* Students who are not attending an online course
* Students who are not registered in a university undergraduate or graduate course.

Primary outcomes:
measure: Academic Self-Concept Scale Score
timeFrame: up to 3 months
measure: PHQ-9 Score
timeFrame: up to 3 months
measure: GAD-7 Score
timeFrame: up to 3 months
measure: Preference of teaching method
timeFrame: up to 3 months
measure: Self perceived academic performance
timeFrame: up to 3 months
measure: Academic grades changes
timeFrame: up to 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Guadalajara
country: Mexico
facility: Instituto Mexicano del Seguro Social
state: Jalisco
Study officials:
References:
Clinical trial NCT01030016: Study of Atenolol Influence on Blood Pressure During Resistance Exercise
Official title: Blood Pressure Response During Resistance Exercise in Hypertensives: Influence of Beta-blockers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Blood Pressure
Exercise
Keywords: resistance exercise
beta-blockers
blood pressure
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
Collaborators: name: Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted: 2009-12-10
Enrollment: 10
Sex: ALL
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The study was designed to investigate if atenolol is able to blunt blood pressure increase during resistance exercise in hypertensive subjects.

Detailed description: The study compared intra-arterial blood pressure responses during leg-extension resistance exercise performed to fatigue at 40, 80 and 100% of 1 RM in hypertensive patients receiving placebo (first) and atenolol (second) on a single blind manner.

Eligibility criteria: Inclusion Criteria:

* hypertension with blood pressure levels below 160/105 mmHg under placebo.
* age between 30 and 60 years
* nonobese

Exclusion Criteria:

* target organ lesion
* cardiovascular risk factor
* cardiovascular disease
* physically active

Primary outcomes:
measure: blood pressure during resistance exercise
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: University of São Paulo
Study officials:
affiliation: University of Sao Paulo
name: Cláudia LM Forjaz, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Sao Paulo
name: Decio Mion Jr, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00354016: Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects
Official title: A Phase III, Multicenter, Uncontrolled, Open-Label Study to Demonstrate Safety and Immunogenicity of a Commercially Available Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 When Administered to Non-Elderly Adult and Elderly Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Influenza
Keywords: influenza
vaccine
Lead sponsor: Novartis
Sponsor class: INDUSTRY
Collaborators: name: Novartis Vaccines
First posted: 2006-07-19
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Due to antigenic changes of influenza viruses, the virus strains used in influenza vaccines are adjusted every year according to WHO (World Health Organization) and CHMP (Committee for Medicinal Products for Human Use) recommendations. Immunogenicity and tolerability of the newly composed vaccines are subject for evaluation in a yearly clinical trial in non-elderly and elderly subjects (CPMP/BWP/214/96).


Eligibility criteria: Inclusion Criteria:

* Healthy adults aged \>18 years

Exclusion Criteria:

* serious chronic diseases or significant acute infections requiring systemic antibiotic treatment
* history of any anaphylaxis, serious vaccine reactions
* hypersensitivity against vaccine components
* history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine
* known or suspected impairment/alteration of immune function
* more than one injection of influenza vaccine received or laboratory confirmed influenza disease
* within last 6 months: influenza vaccination received

Primary outcomes:
measure: antibody titers to each influenza strain measured by hemagglutination inhibition (HI) test on Day 0 and on Day 21
Secondary outcomes:
measure: safety of a single IM dose of the split influenza vaccine using solicited local and systemic reactions and adverse event reporting
Other outcomes:
Locations:
city: Herborn
country: Germany
facility: Werksarztzentrum Herborn, Westerwaldstr 36,
city: Marburg
country: Germany
facility: Betriebsarztlicher Dienst, Universitat Marburg, Robert-Koch-Str, 5,
Study officials:
affiliation: Novartis Vaccines & Diagnostics
name: Novartis Vaccines - Drug Information Services
role: STUDY_CHAIR
References:
Clinical trial NCT04070716: 3-dimensional Versus 2-dimensional Laparoscopy for Myomectomy
Official title: 3-dimensional Versus 2-dimensional Laparoscopy for Myomectomy: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Laparoscopy
Lead sponsor: Kangbuk Samsung Hospital
Sponsor class: OTHER
First posted: 2019-08-28
Enrollment: 64
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare the surgical outcomes and efficacy of 3-dimensional (3D) versus 2-dimensional (2D) imaging systems in laparoscopic myomectomy..

Detailed description: Laparoscopy is founded as a treatment of choice for benign uterine disease. The advantages of laparoscopic surgery over conventional open surgery are less pain, shorter recovery time, shorter hospital stay, and consequently faster return to normal activity as well as better cosmetic effects. However, laparoscopic surgery is more demanding compared with open surgery because operators should project three-dimensional (3D) field through a two-dimensional (2D) monitor.

However, to date, studies examining the possible benefits and drawbacks of 3D imaging system versus 2D in laparoscopic surgery have brought about conflicting results. Moreover, there have been few studies comparing the surgical outcomes of 3D and 2D laparoscopic laparoscopic myomectomy. The aim of this study is to compare the surgical outcomes and efficacy of 3-dimensional (3D) versus 2-dimensional (2D) imaging systems in laparoscopic myomectomy..

Eligibility criteria: Inclusion Criteria:

* Uterine myoma requiring laparoscopic myomectomy
* American Society of Anesthesiologists physical status (ASAPS) classification I-II
* absence of pregnancy at the time of surgery.

Exclusion Criteria:

* any suspicious findings of malignant gynecologic diseases,

Primary outcomes:
measure: Amount of operative blood loss
timeFrame: At the time of surgery
Secondary outcomes:
measure: Operative time
timeFrame: At the day of surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Kangbuk Samsung Hospital
Study officials:
affiliation: Kangbuk Samsung Hospital, Seoul, Republic of Korea
name: Taejong Song, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00486616: Examination of Double-Lumen Tube Placement by Functional Electrical Impedance Tomography
Official title: Examination of Double-Lumen Tube Placement: Functional Electrical Impedance Tomography Versus Fibreoptic Bronchoscopy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Double-Lumen Tube Placement
One-Lung Ventilation
Lead sponsor: University Hospital Freiburg
Sponsor class: OTHER
First posted: 2007-06-14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: The purpose of this study is to determine whether functional electrical impedance tomography is suitable for examination of double-lumen tube placement compared with fibreoptic evaluation.


Eligibility criteria: Inclusion Criteria:

* consent of the patient
* intubation with left- or right-sided double-lumen tube
* age \>= 18 years

Exclusion Criteria:

* refusal by the patient
* contraindications for EIT-measurement (e.g. pacemaker, pregnancy)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Freiburg
country: Germany
facility: University Hospital Freiburg
Study officials:
affiliation: Department of Anesthesia and Critical Care Medicine, University Hospital Freiburg
name: Daniel Steinmann, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00198016: Coil Embolization of Coronary Artery Fistulas
Official title: Coil Embolization of Coronary Artery Fistulas: A Single Centre Experience
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: C14
C14907933
C14907933125
G09330582163324
C14280647250
Keywords: coronary fistulas.
coils embolization.
Lead sponsor: HOSPITEN
Sponsor class: OTHER
First posted: 2005-09-20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: Background and Purpose: Congenital coronary artery fistula (CAF) is an uncommon anomaly. In some patients they can became symptomatic, associated with significant morbidity and mortality. We report our experience in percutaneous treatment of CAF.

Detailed description: Congenital coronary artery fistula (CAF) can be defined as a direct communication of a coronary artery with a cardiac chamber, great vessel, or other vascular structure, bypassing the myocardial capillary bed.

CAF is an uncommon anomaly, occurring as an incidental finding in 0.1% to 0.2% of coronary angiograms. They are not gender specific. Many patients have symptoms like congestive heart failure, infective endocarditis, myocardial ischemia, or rupture of an aneurismal fistula. Surgical closure of coronary artery fistula was initially reported in 1983 with low rates of morbidity and mortality.

Percutaneous treatment appeared as an alternative to surgery. Transcatheter closure of CAF was first utilized in 1983. Along this years, with experience and improvements in catheterization equipment and occlusion devices, CAF occlusion have been successfully performed using microcoils.

We report our experience in using microcoils to percutaneous treatment of coronary fistulas.

Eligibility criteria: Inclusion Criteria:

* Coronary artery fistulas
* Clinical diagnosis of angina, myocardial infarction, left ventricular insufficiency, ventricular enlargement

Exclusion Criteria:

* Age \<18 or \> 85 years
* Cardiogenic shock _ severe ventricular enlargement

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Santa Cruz
country: Spain
facility: HOSPITEN
state: Tenerife
Study officials:
affiliation: HOSPITEN
name: Zuheir Kabbani, Cardiology
role: STUDY_DIRECTOR
References:
Clinical trial NCT05425316: Speech in Hepatic Encephalopathy (HE)
Official title: Analysis of Acoustic, Lexical, and Syntactic Speech Features in Hepatic Encephalopathy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatic Encephalopathy
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: Winterlight Labs
First posted: 2022-06-21
Enrollment: 251
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study population consists of adult outpatients who are evaluated at the University of Michigan Hepatology Clinic.

Brief summary: This is an observational study that will test the clinical significance of speech features in patients with cirrhosis. It aims to assess if speech is associated with cognitive function at baseline, if speech predicts changes in cognition, and if speech predicts future events of hepatic encephalopathy (cirrhosis-related confusion), as well as to assess the dynamics of speech over time, especially with episodes of overt hepatic encephalopathy (OHE) and treatment interventions.


Eligibility criteria: Inclusion Criteria for Patients with Cirrhosis:

* Cirrhosis, as diagnosed by imaging, elastography, biopsy, or decompensation
* Able to provide informed consent in English

Exclusion Criteria for Patients with Cirrhosis:

* Neurodegenerative disorder (other than hepatic encephalopathy) including Alzheimer's disease and dementia
* Prior stroke or Transischemic Attack (TIA)
* English not primary language for communication

Inclusion Criteria for Patients without Cirrhosis:

* Able to provide informed consent in English
* Fibroscan with stiffness \<7 kPa

Exclusion Criteria for Patients without Cirrhosis:

* Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \>5 times the upper limit of normal in the last year
* History of cirrhosis by imaging or histology or clinical decompensation
* Neurodegenerative disorder (other than hepatic encephalopathy) including Alzheimer's disease and dementia
* Prior stroke or TIA

Primary outcomes:
measure: Change in Psychometric Hepatic Encephalopathy Score (PHES) from Baseline to 6 Months
timeFrame: 6 Months
measure: Change in Psychometric Hepatic Encephalopathy Score (PHES) from Baseline to 12 Months
timeFrame: 12 Months
measure: Speech Assessments
timeFrame: 12 Months
measure: Time to Overt Hepatic Encephalopathy (HE)
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Hepatology and Transplant Clinic
state: Michigan
Study officials:
affiliation: University of Michigan
name: Patricia Bloom, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05680116: The Effect of Wearable Vibration Therapy on Shoulder Functionality in Individuals Receiving Adjuvant Radiotherapy After Breast Cancer Surgery
Official title: The Effect of Wearable Vibration Therapy on Shoulder Functionality in Individuals Receiving Adjuvant Radiotherapy After Breast Cancer Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Lead sponsor: Acibadem University
Sponsor class: OTHER
First posted: 2023-01-11
Enrollment: 38
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of our study is to investigate the effect of vibration therapy to be applied to patients undergoing breast cancer surgery and adjuvant radiotherapy on upper extremity joint range of motion, muscle strength, grip strength, pain, functionality, and quality of life.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with breast cancer, undergoing breast-conserving surgery or having a total mastectomy and undergoing axillary lymph node dissection during surgery
* Cases that will start radiotherapy after surgery
* Being over 18 years old
* Absence of limitation in shoulder joint range of motion in preoperative evaluations.
* No speech and hearing problems
* Volunteering of the patients included in the study

Exclusion Criteria:

* Having previously undergone ipsilateral or contralateral breast cancer surgery
* Presence of active or metastatic cancer focus
* Presence of a neurological disease or orthopedic surgery affecting upper extremity functionality
* Carrying a pacemaker
* Presence of infection and open wound
* Finding a post-surgical drain
* Cases with mental and cooperation problems

Primary outcomes:
measure: Muscle strength
timeFrame: 6 weeks
measure: Range of motion
timeFrame: 6 weeks
Secondary outcomes:
measure: Pain - Visual Analogue Scale
timeFrame: 6 weeks
measure: Grip strength
timeFrame: 6 weeks
measure: Disability
timeFrame: 6 weeks
measure: Quality of Life- Functional Assessment of Cancer Therapy-Breast" (FACT-B)
timeFrame: 6 weeks
measure: Tone - Myoton® PRO
timeFrame: 6 weeks
measure: Stiffness of Muscle- Myoton® PRO
timeFrame: 6 weeks
measure: Elasticity of Muscle -Myoton® PRO
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Professor Cemil Taşcıoğlu Training and Research Hospital
Study officials:
affiliation: Acibadem University
name: Özlem Feyzioğlu, PhD
role: PRINCIPAL_INVESTIGATOR
References: